Upgrade to SI Premium - Free Trial

Goldman Sachs Reiterates Neutral Rating on United Therapeutics Corp. (UTHR)

August 20, 2024 4:51 AM
Goldman Sachs analyst Chris Shibutani reiterated a Neutral rating and $243.00 price target on United Therapeutics Corp. (NASDAQ: UTHR).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles